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Background:  Inﬂammation  plays  a signiﬁcant  role  in  acute  coronary  syndrome  (ACS)  and  type  2 dia-
betes  mellitus  (DM).  There  may  be similar  inﬂammatory  changes  in  non-DM  patients  with  ST elevation
myocardial  infarction  (STEMI)  and  DM  patients  with  stable  angina  (SA),  and  DM  patients  with  STEMI
may  have  more  severe  changes  than  the  former  two  groups.  The  objectives  of this  study  were  to inves-
tigate  whether  the  level  of inﬂammation  was similar  in  patients  with  non-DM  STEMI  and  DM  SA, and  to
evaluate  whether  the  changes  in the  level  of inﬂammation  were  more  severe  in patients  with  DM  STEMI
compared  to the other  two groups.
Methods  and  results:  A variety  of  inﬂammatory  markers  including:  highly  sensitive  C-reactive  pro-
tein  (hsCRP),  erythrocyte  sedimentation  rate  (ESR),  interleukin-6  (IL-6),  IL-18,  vascular  cell  adhesion
molecule-1  (VCAM-1),  and  matrix  metallopeptidase-9  (MMP-9)  as  well  as insulin  resistance  were  com-
pared  among  the  three  groups:  DM  STEMI  (90  patients),  DM  SA  (91  patients),  and  non-DM  STEMI  (76
patients).  Inﬂammatory  marker  levels  were  not  signiﬁcantly  different  between  the  DM  SA and  non-DM
STEMI  groups.  However,  hsCRP  and  IL-6 were  increased  in  the  DM  STEMI  compared  to  the DM  SA  patients
(p  =  0.005  and p  =  0.004,  respectively).  In addition,  hsCRP,  ESR,  and  IL-18  were  increased  in the  DM STEMI
compared  to  the  non-DM  STEMI  patients  (p  =  0.017,  p =  0.020,  and  p  =  0.033,  respectively).  Furthermore,
the  fasting  insulin  and  the homeostasis  model  assessment  were  signiﬁcantly  increased  in  the  DM  STEMI
compared  to the DM  SA  patients  (p = 0.04 and  p  = 0.004,  respectively).
Conclusions:  DM  SA and  non-DM  STEMI  may  have  similar  inﬂammatory  changes.  DM  STEMI  may  be a
more  severe  inﬂammatory  condition  compared  to patients  with  DM  SA  or non-DM  STEMI.
2  Jap© 201
. Introduction
Type 2 diabetes mellitus (DM) is a major independent risk factor
or cardiovascular disease (CVD) [1].  According to the updated US
ational Cholesterol Education Program (NCEP) Adult Treatment
anel (ATP) III guidelines, patients with DM are categorized as hav-
ng the highest level of risk for recurrent CVD events, and they are
n the same risk category as patients with acute coronary syndrome
ACS) [2].  In a previous report, Haffner et al. compared DM patients
n = 1059) and non-DM patients (n = 1373) [3] and found that the
even-year incidence of myocardial infarction is similar in non-DM
atients with preexisting coronary heart disease (CHD) and DM
∗ Corresponding author at: Department of Cardiology, Cardiovascular Center,
orea University Hospital, 126-1, 5ka, Anam-dong, Sungbuk-ku, Seoul 136-705,
epublic of Korea. Tel.: +82 2 920 5445; fax: +82 2 927 1478.
E-mail address: jhpark3992@naver.com (J.H. Park).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.03.006anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
patients without CHD; these ﬁndings suggest that patients with
DM may  have a similar degree of risk as patients with preexisting
CHD.
Inﬂammation plays a signiﬁcant role in both CHD and DM.
Inﬂammation can lead to atherogenesis, atheromatous plaque rup-
ture, and thrombus formation that cause ACS [4].  Inﬂammation is
the major pathogenetic mechanism associated with the vascular
complications of DM [5,6], and the hyperglycemia associated with
DM can lead to inﬂammation [7].  These prior studies suggest that
there may  be similar inﬂammatory changes in non-DM patients
with myocardial infarction and DM patients without myocardial
infarction, and that DM patients with myocardial infarction may
have more severe inﬂammatory chances than the former two
groups. Therefore, comparison of various inﬂammatory markers
among three experimental groups was  investigated in this study.
The aim of this study was  to determine whether the inﬂamma-
tory changes were similar in patients with non-DM ST elevation
myocardial infarction (STEMI) and DM stable angina (SA), and to
vier Ltd. All rights reserved.
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valuate whether the inﬂammatory changes in patients with DM
TEMI were more severe than in the former two groups. A variety
f inﬂammatory markers were compared among the three experi-
ental groups.
. Methods
.1. Study population and study design
Patients with STEMI or SA at the Korea University Anam Hospital
ardiovascular Center were studied from January 2005 to January
008. DM and non-DM patients with STEMI and DM patients with
A were included in this study. All patients who received intracoro-
ary sirolimus-eluting stent implantation were included. Patients
ith prior history of interventional or surgical treatment for coro-
ary artery disease, coronary artery total occlusion, C-reactive
rotein (CRP) >15 mg/dL, or a contraindication for antiplatelet or
nticoagulation therapy was excluded from this study. Patients
ith a systemic inﬂammatory process, cancer, active infection, or
ebrile status were also not included in the study. The patients were
ivided into three groups according to their diagnosis: DM STEMI
n = 90), DM SA (n = 91), and non-DM STEMI (n = 76). We included
nly STEMI among ACS because the study was designed to compare
atients with severe inﬂammation.
DM was deﬁned as a history of DM,  a fasting plasma glucose
oncentration ≥ 126 mg/dL, or the use of hypoglycemic medica-
ions. Systemic hypertension was deﬁned as a systolic blood
ressure ≥ 140 mmHg, or a diastolic pressure ≥ 90 mmHg, or the
se of antihypertensive medication. For patients with DM,  systemic
ypertension was deﬁned as a systolic blood pressure ≥ 130 mmHg,
iastolic pressure ≥ 80 mmHg.
STEMI was diagnosed based on clinical symptoms, electrocar-
iographic evidence of >0.1 mV ST elevation in at least 2 leads,
nd >2-fold increase in serum creatine kinase-MB concentration
rom the upper limit of the normal range. Coronary angiography
onﬁrmed the occlusion of a coronary artery with thrombolysis in
yocardial infarction grade ﬂow <3.
Balloon angioplasty and coronary stent implantation were per-
ormed in all patients based on standard clinical practice. Arterial
lood samples were drawn from each patient during the inter-
ention, and plasma was obtained from these blood samples.
nﬂammatory markers such as highly sensitive (hs) CRP, erythro-
yte sedimentation rate (ESR), interleukin-6 (IL-6), IL-18, vascular
ell adhesion molecule-1 (VCAM-1), matrix metallopeptidase-9
MMP-9) and lipid proﬁles such as total cholesterol, triglyceride,
nd high-density lipoprotein (HDL), and low-density lipoprotein
LDL) were measured from the plasma samples, and compared
mong the three groups. Insulin resistance markers such as the
asal insulin, the homeostasis model assessment (HOMA) index,
isfatin, and retinol binding protein 4 (RBP4) were measured and
ompared between the patients with DM STEMI and DM SA. This
tudy was approved by the institutional review board, and all par-
icipants provided written informed consent to participate.
.2. Angiographic analysis and intravascular ultrasound
easurements
Coronary angiograms were obtained at baseline and immedi-
tely after coronary stenting. Two identical orthogonal views were
btained after the intracoronary administration of nitrates and
tored on a digital CD-ROM. All angiographic and clinical data were
nalyzed at the Korea University Anam Hospital Core Laboratory.
nd-diastolic frames were chosen for quantitative analysis, which
ere performed using a computer-based TCS system, Version 2.02
Medcon Inc., Tel-Aviv, Israel) by an operator who was unaware oflogy 60 (2012) 204–209 205
the patient information. The reference diameter, minimal luminal
diameter, percentage of stenosis, and lesion length were calculated
as the average value of the two orthogonal views. The average diam-
eter of the normal segments proximal and distal to the treated
lesion was used as the reference diameter. Balloon angioplasty and
stent implantation were performed according to standard clinical
practice.
2.3. Laboratory analysis
The hsCRP concentration was quantiﬁed using a latex neph-
elometer II (Dade Behring Inc., Newark, DE,  USA). Forty nine
individuals with hsCRP levels equal to or more than 15 mg/L were
excluded from the statistical analysis because hsCRP values more
than 15 mg/L indicate acute infection or systemic inﬂammation
[8]. The ESR was measured by a modiﬁed Westergren method.
High-sensitivity IL-6 was  also measured by a sandwich enzyme
linked immunoassay (ELISA) with a minimum detectable level of
0.16 pg/mL (ALPCO Diagnostics, Salem, NH, USA). IL-18, VCAM-1,
and MMP-9 were measured by ELISA (R & D Systems, Minneapo-
lis, MN,  USA). The total cholesterol, triglyceride, HDL cholesterol,
and LDL cholesterol concentrations were determined by enzy-
matic methods using standard biochemical procedures on a B.M.
Hitachi automated clinical chemistry analyzer (Hitachi, Tokyo,
Japan). Serum insulin was  measured by microparticle enzyme
immunoassay. Insulin resistance was assessed by the HOMA,
calculated as (fasting serum insulin [U/mL] × fasting serum glu-
cose [mmol/L])/22.5. Plasma visfatin and RBP4 concentration were
assessed by ELISA.
2.4. Statistical analysis
Data are expressed as the mean ± SD for continuous variables,
and data for the categorical variables are expressed as the num-
ber and the percentage of patients. Two by three Cross-tabulation
analysis was  used to compare the categorical variables among the
three groups: gender, medical history, medication at baseline. In
addition, the four by three Cross-tabulation analysis was  used to
compare the distribution of target vessels among the three groups.
The Chi-square test was used for the categorical variables of the
two DM groups; DM treatment and medication in the DM STEMI
and DM SA groups. Analysis of variance (ANOVA) was  used to com-
pare continuous variables among the three groups including: age,
body mass index (BMI), angiographic characteristics, lipid proﬁles,
and inﬂammatory markers. A Scheffe test was  used for post hoc
analysis followed by ANOVA if there was  a statistical signiﬁcance.
The independent samples t-test was used to compare continuous
variables between the two  DM groups. A p-value < 0.05 was consid-
ered statistically signiﬁcant. SPSS software (version 10.0) was used
for analyses (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Study population and clinical ﬁndings
The BMI  was  higher in the DM SA group than in the other groups
(p = 0.005, two  by three Cross tabulation analysis), and the history of
hypertension and family history of premature CHD differed among
the three groups (p = 0.02 and p = 0.02, respectively) (Table 1). The
other baseline characteristics were similar among the three groups.
The duration of DM was 4.47 ± 5.9 (years) in the DM STEMI group
and 5.63 ± 8.5 in the DM SA group. The baseline hemoglobin A1c
level was  7.57 ± 1.4% in the DM STEMI group, 8.44 ± 9.9% in the DM
SA group, and 5.5 ± 0.78% in the non-DM STEMI group.
The distribution of target vessels was similar among the three
groups (Table 2). There was no signiﬁcant difference in the baseline
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Table  1
Baseline characteristics of the three experimental groups.
DM STEMI DM SA Non-DM STEMI p-Value
(N  = 90) (N = 91) (N = 76)
Age – years 64.11 ± 2.10 62.52 ± 1.98 63.50 ± 2.72 0.584
Gender – Male no. (%) 62 (68.9%) 50 (54.9%) 52 (68.4%) 0.863
Body-mass index – kg/m2* 24.51a 25.55b 24.17a 0.005
Hypertension – no. (%) 53 (58.9%) 69 (75.8%) 30 (39.5%) 0.020
Dyslipidemia – no. (%) 41 (45.6%) 41 (45.1%) 27 (35.5%) 0.333
Current smoker – no. (%) 37 (41.1%) 35 (38.5%) 29 (38.2%) 0.691
FHx  of premature CHD – no. (%) 1 (1.1%) 2 (2.2%) 6 (7.9%) 0.020
CABG  history – no. (%) 3 (3.3%) 4 (4.3%) 1 (1.3%) 0.484
Medication at baseline
Aspirin use – no. (%) 87 (96.7%) 89 (97.8%) 74 (97.4%) 0.768
Cilostazol use – no. (%) 11 (12.2%) 9 (9.9%) 10 (13.2%) 0.878
Warfarin use – no. (%) 3 (3.3%) 1 (1.1%) 1 (1.3%) 0.331
Clopidogrel use – no. (%) 87 (96.7%) 91 (100%) 74 (97.4%) 0.683
Diltiazem use – no. (%) 2 (2.2%) 15 (16.5%) 3 (3.9%) 0.545
Nitrate use – no. (%) 29 (32.2%) 31 (34.1%) 23 (30.3%) 0.806
Nicorandil use – no. (%) 16 (17.8%) 10 (11.0%) 14 (18.4%) 0.969
Trimetazidine use – no. (%) 15 (16.7%) 7 (7.7%) 16 (21.1%) 0.502
ACEI  or ARB use – no. (%) 72 (80.0%) 67 (73.6%) 56 (73.7%) 0.329
Beta-blocker use – no. (%) 66 (73.3%) 58 (63.7%) 51 (75.0%) 0.362
CCB  use – no. (%) 3 (3.3%) 25 (27.5%) 1 (1.3%) 0.918
Statin use – no. (%) 81 (90.0%) 83 (91.2%) 66 (86.8%) 0.532
DM  treatment – no. (%)
None or exercise 15 (16.7%) 12 (13.1%) – 0.384
Oral  medication 66 (73.3%) 67 (73.6%)
Insulin 9 (10.0%) 12 (13.2%)
Oral medication about DM – no. (%)
Sulfonylurea 59 (65.6%) 57 (62.6%) 0.400
Metformin 33 (36.7%) 25 (27.5%) – 0.122
Thiazolidinediones 4 (4.4%) 11 (12.1%) 0.052
Nateglinide 2 (2.2%) 0 (0%) 0.246
Alpha-glucosidase inhibitors 18 (20.0%) 17 (18.7%) 0.485
Age and BMI  data are mean ± SD.
DM,  type 2 diabetes mellitus; STEMI, ST segment elevation myocardial infarction; SA, stable angina; CHD, coronary heart disease; FHx, family history; CABG, coronary artery
bypass  graft; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium-channel blocker.
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eference diameter among the three groups. However, the mini-
al  lumen diameter and percentage of stenosis were different: theTEMI groups (DM STEMI and non-DM STEMI) had more severe
tenosis than the DM SA group (p < 0.001). Therefore, the acute
ain was wider in the DM STEMI and non-DM STEMI group than in
able 2
ngiographic characteristics of the three experimental groups.
DM STEMI
(N  = 90) 
Results of angiographic characteristics
Target coronary artery – no. (%)
Left main 0 (0%) 
Left  anterior descending artery 54 (60.0%) 
Left  circumﬂex artery 15 (16.7%) 
Right  21 (23.3%) 
Baseline
Reference diameter (mm)  2.70 ± 0.10 
Minimal lumen diameter (mm)* 0.42 ± 0.10a 
Percentage of stenosis (%)a,* 83.80 ± 3.55a 
Postprocedure
Reference diameter (mm)  3.01 ± 0.10 
Minimal lumen diameter (mm)  2.78 ± 0.10 
Percentage of stenosis (%) 7.60 ± 1.16 
Acute  gain (mm)b,* 2.32 ± 0.15a 
eference diameter, minimal lumen diameter, percentage of stenosis, acute gain are mea
M,  type 2 diabetes mellitus; STEMI, ST segment elevation myocardial infarction; SA, sta
tatistical tests were carried out by one-way analysis of variance followed by post hoc
ompare the distribution of target vessels among the three groups.
a Percentage of stenosis = (Reference diameter − Minimal lumen diameter)/Reference d
b Acute gain = Postprocedure minimal lumen diameter − Baseline minimal lumen diam
* The same letters indicate non-signiﬁcant difference between groups based on Scheffeheffe test. In addition, two by three Cross-tabulation analysis was used to compare
 baseline.
 test for multiple comparison.
the DM SA (p < 0.001). The other angiographic characteristics were
similar among the three groups.The lipid proﬁles showed a signiﬁcant difference in the triglyc-
eride, HDL, and triglyceride/HDL ratio among the three groups
(Table 3). The fasting insulin and HOMA, which are insulin
DM SA Non-DM STEMI p-Value
(N = 91) (N = 76)
7 (7.7%) 0 (0%) 0.532
43 (47.3%) 51 (67.1%)
21 (23.1%) 10 (13.2%)
20 (22.0%) 15 (19.7%)
2.68 ± 0.10 2.81 ± 0.12 0.203
0.88 ± 0.11b 0.32 ± 0.11a <0.001
66.15 ± 3.85b 87.28 ± 4.64a <0.001
2.97 ± 0.09 3.08 ± 0.13 0.384
2.72 ± 0.09 2.84 ± 0.12 0.271
8.60 ± 1.06 7.78 ± 1.27 0.389
1.78 ± 0.12b 2.39 ± 0.21a <0.001
n ± SD.
ble angina.
 Scheffe test. In addition, the four by three Cross-tabulation analysis was used to
iameter × 100.
eter.
 test for multiple comparison.
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Table  3
Comparison of lipid proﬁles among the three experimental groups.
DM STEMI DM SA Non-DM STEMI p-Value
(N  = 90) (N = 91) (N = 76)
Total cholesterol 157.81 ± 10.00 171.51 ± 9.44 164.09 ± 9.02 0.119
Triglyceride* 115.40 ± 102.77a 146.86 ± 17.61b 101.53 ± 14.94a <0.001
HDL* 41.76 ± 1.90a 46.20 ± 2.28b 45.20 ± 2.65a,b 0.014
LDL 100.22 ± 7.80 104.69 ± 8.45 106.23 ± 8.21 0.566
TG/HDL ratio* 2.92 ± 0.34a,b 3.43 ± 0.48a 2.43 ± 0.39b 0.04
LDL/HDL ratio 2.45 ± 0.19 2.35 ± 0.21 2.51 ± 0.25 0.585
Data are mean ± SD.
DM,  type 2 diabetes mellitus; STEMI, ST segment elevation myocardial infarction; SA, stable angina; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG,
t
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esistance markers, were signiﬁcantly increased in the DM STEMI
roup compared to the DM SA group (p = 0.04 and 0.004, respec-
ively) (Table 4).
.2. Comparison of inﬂammatory markers among the three
xperimental groups
Inﬂammatory markers such as hsCRP, ESR, IL-6, IL-18, VCAM,
nd MMP-9 were compared among the three experimental groups
Fig. 1). The inﬂammatory markers were not signiﬁcantly different
n the DM SA and non-DM STEMI groups. However, the hsCRP and
L-6 were increased in DM STEMI compared to DM SA (p = 0.005
nd p = 0.004, respectively). In addition, the hsCRP, ESR, and IL-18
ere increased in DM STEMI compared to non-DM STEMI (p = 0.017,
 = 0.020, and p = 0.033, respectively).
. Discussion
In this study, there was no signiﬁcant difference in the inﬂam-
atory markers, such as hsCRP, ESR, IL-6, IL-18, VCAM-1, and
MP-9, between the non-DM STEMI and DM SA groups. Clinically,
therosclerosis can precede DM;  both the ACS and DM share com-
on  risk factors such as obesity, insulin resistance, dyslipidemia,
nd hypertension, the ‘common soil’ hypothesis or metabolic syn-
rome [9].  In addition, Haffner et al. showed that subjects with DM,
ithout myocardial infarction, have a similar risk for myocardial
nfarction as non-DM subjects with a previous myocardial infarc-
ion [3]. Furthermore, the NCEP ATP III has proposed DM as a CHD
quivalent [2],  supporting the ‘common soil’ hypothesis. Inﬂam-
ation is thought to play an important role in both ACS and DM;
ncreased levels of inﬂammatory markers have been documented in
oth ACS and DM.  CRP is the prototypical acute phase reactant that
as been found in the majority of patients with unstable angina.
ncreased levels of CRP have been signiﬁcantly associated with
nfavorable outcomes [10,11]. Decreased insulin sensitivity may
able 4
omparison of insulin resistance markers between DM STEMI and DM SA.
DM STEMI DM SA p-Value
(N = 73) (N = 79)
Insulin 5.64 ± 1.52 3.85 ± 0.79 0.04
Hemoglobin A1c 7.59 ± 0.35 8.58 ± 2.41 0.151
HOMA 49.30 ± 17.46 22.40 ± 5.03 0.004
Visfatin 4.03 ± 0.81 3.25 ± 0.73 0.155
RBP4 59.81 ± 4.70 64.19 ± 5.81 0.249
ata are mean ± SD.
M,  type 2 diabetes mellitus; STEMI, ST segment elevation myocardial infarction;
A, stable angina; HOMA, homeostasis model assessment; RBP4, retinol binding pro-
ein  4.
OMA was calculated as (fasting serum insulin [U/mL] × fasting serum glu-
ose[mmol/L])/22.5.
tatistical tests were carried out by Student’s t-test.heffe test.
 test for multiple comparison.
lead to enhanced CRP expression by counteracting the physiological
effects of insulin on hepatic acute-phase protein synthesis [12,13].
A Reykjavik study (2003) showed that the ESR was  a risk factor for
CHD [14]. In a large, healthy European cohort, the ESR was associ-
ated with insulin sensitivity [15]. IL-6 is correlated with CRP; they
are the major determinants for liver production of acute-phase pro-
teins via direct stimulation of hepatocytes [16,17]. Previous reports
showed that IL-6 is increased in unstable angina, and is associ-
ated with the patient prognosis. IL-6 has proinﬂammatory [16] and
procoagulant [18] properties that may  play a role in the patho-
physiology of ACS. IL-18 is a proinﬂammatory cytokine involved in
the development of cell-mediated cytotoxicity, particularly T cells,
which regulate the immune response. IL-18 induces interferon-
production by T lymphocytes and natural killer cells, and appears
to be directly related to atherosclerotic plaque rupture [4,19,20].
Previous studies have shown that IL-6 [11] and IL-18 [21–23] are
elevated in subjects with DM.  VCAM-1 has been associated with
adverse events in patients with ischemic heart disease [24,25].
It mediates rolling and transendothelial migration of circulating
leukocytes into the intima [26]. In rabbits that ingest an atherogenic
diet, expression of the adhesion molecule VCAM-1 precedes the
accumulation of leukocytes in the intima [27]. Jager et al. showed
that increased VCAM-1 levels are signiﬁcantly associated with an
increased risk of cardiovascular mortality with DM [28]. MMP-
9 is member of the MMP  family, associated with the fragility of
the ﬁbrous cap. Human atherosclerotic lesions overexpress human
interstitial collagenases, such as MMP-9 that specialize in break-
ing down ﬁbrillar collagen in the plaque’s ﬁbrous cap [29]. Uemura
et al. demonstrated that MMP-9 expression is upregulated during
hyperglycemia [30]. Bahceci showed that men with DM,  without
CAD, have similar CRP levels to non-DM men with CAD, supporting
the ‘common soil’ hypothesis [31]. The results of this study show
that not only CRP levels but also ESR, IL-6, IL-18, VCAM-1, and MMP-
9 levels were not signiﬁcantly different between the non-DM STEMI
and DM SA groups, supporting the ‘common soil’ hypothesis.
In addition, the ﬁndings of this study showed that the mean
hsCRP level of the DM STEMI group was  not only higher than the
DM SA group, but also higher than the non-DM STEMI group. In a
previous study, Bahceci showed that hsCRP levels were higher in
patients with DM CHD than in patients with DM SA or non-DM CHD
[31]. The association of DM and STEMI appears to be correlated with
higher hsCRP levels. DM may  contribute to an extra-increment in
the hsCRP levels in patients with STEMI. Indeed DM is associated
with a high risk of mortality from CHD and this high risk may  be
associated with the inﬂammatory factors. However, in this study,
the other inﬂammatory markers showed results that differed from
the CRP. ESR and IL-18 were higher in the DM STEMI group than
the non-DM STEMI group, but there was no signiﬁcant difference
between the DM STEMI and DM SA groups. The IL-6 was higher
in the DM STEMI group than in the DM SA group, but there was
no signiﬁcant difference between DM STEMI and non-DM STEMI
208 J.M. Heo et al. / Journal of Cardiology 60 (2012) 204–209
Fig. 1. Comparison of inﬂammatory markers among the three experimental groups: highly sensitive C-reactive protein (hsCRP), erythrocyte sedimentation rate (ESR),
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nnterleukin-6 (IL-6), IL-18, vascular cell adhesion molecule-1 (VCAM-1), matrix me
atient  during the intervention and compared among the three experimental grou
table  angina; signiﬁcantly different between two  groups, *p < 0.05, **p < 0.01 (by on
roups. Moreover, the VCAM-1 and MMP-9 were not signiﬁcantly
ifferent among the three experimental groups. The explanation
or these results is unclear. One possible explanation is the dif-
erent properties of inﬂammatory markers. CRP is a nonspeciﬁc
nﬂammatory marker; its nonspeciﬁcity serves as a barometer for
nﬂammation regardless of the source of that inﬂammation. Since
any inﬂammatory stimuli may  contribute to atherogenesis and
M, CRP might be useful to assess the inﬂammatory burden as a
imple gauge [32]. And, according to a recent study, CRP was one of
he independent predictors of 3-year mortality in STEMI [33]. Other
nﬂammatory markers, such as IL-6, IL-18, VCAM-1, and MMP-9,
epresent various stages of the inﬂammatory process. Because ACS
nd DM may  not have all of the same inﬂammatory conditions,
ome of the inﬂammatory markers may  increase and others may
ot increase in STEMI or DM.  However, the ESR, which is a nonspe-
iﬁc inﬂammatory marker like CRP, had results that differed from
RP. Another possible explanation is measurement error. Currently,
ther inﬂammatory markers are inferior to hsCRP as practical diag-
ostic and prognostic tools, because of relatively short half-life,eptidase-9 (MMP-9) were measured from arterial blood sample drawn from each
,  type 2 diabetes mellitus; STEMI, ST segment elevation myocardial infarction; SA,
y  analysis of variance followed by post hoc Scheffe test).
lack of international standards and robust, reproducible assays
[32].
4.1. Study limitations
First, the absence of a non-DM SA group as a control group was  a
limitation of this study. Because the aim of this study was  mainly to
compare the DM SA and non-DM STEMI groups, the study does not
include a non-DM SA control group. As a result, the levels of inﬂam-
matory markers could not be conﬁrmed to be actually increased in
the DM SA group or non-DM STEMI group compared to the non-DM
SA. However, many previous studies have shown that the levels
of inﬂammatory markers are increased in patients with DM and
patients with a myocardial infarction [2–28]. According to previ-
ous studies, the non-DM SA group would be predicted to have lower
levels of inﬂammatory markers than the three groups in this study.
Another limitation was  the unequal distribution of the clinical
risk factors among the three groups, such as the BMI, as well as the
triglyceride and HDL levels (Tables 1 and 3). Due to the unequal
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istribution of the clinical risk factors among the three groups,
he associations among these clinical risk factors and inﬂammatory
arkers were assessed. The trend of the results did not differ before
nd after adjustment by the analysis of covariance (ANCOVA). How-
ver, the clinical risk factors such as past history of hypertension
nd family history of premature CHD could not be adjusted for
ecause they are dichotomous variables.
The ﬁnal limitation is the interpretation of the inﬂammatory
arker levels; a similar inﬂammatory marker level may  not be
he same as a similar inﬂammatory mechanism. Various factors,
uch as age, gender, ethnicity, season, exercise, body mass, life
tyle behavior, medications, specimen collection and handling, and
ther risk factors, inﬂuence the levels of the inﬂammatory markers
32]. However, the assessment of overall severity of disease may  be
ore clinically useful. Identiﬁcation of the pathogenic mechanisms
f each patient is difﬁcult to determine, especially with regard to
hronic inﬂammatory disease, such as with CHD and DM.
. Conclusion
DM SA and non-DM STEMI may  have similar severity of overall
nﬂammation or similar inﬂammatory changes. DM STEMI may  be a
ore severe inﬂammatory condition than DM SA or non-DM STEMI.
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